Nanoscint (Human Serum Albumin)

Human Serum Albumin, the active ingredient in Nanoscint, is a plasma protein (albumin) presented as a sterile solution for injection for intravenous or subcutaneous use. It is employed to treat hypoalbuminemia and to expand intravascular volume in patients with burns, hypovolemic shock, or other conditions requiring restoration of plasma oncotic pressure.

GNH USA supplies Nanoscint as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Nanoscint, a human serum albumin solution, is used in clinical situations that require plasma protein replacement or rapid intravascular volume expansion.

- Hypoalbuminemia: restores plasma oncotic pressure and raises serum albumin levels. - Burn injuries: provides volume expansion and supports fluid resuscitation. - Hypovolemic shock: increases circulating volume to stabilize hemodynamics. - Surgical or trauma patients: maintains oncotic balance during peri‑operative fluid management.

Nanoscint may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Fever: transient elevation of body temperature. - Headache: mild to moderate intensity. - Nausea: occasional feeling of queasiness. - Injection site pain: localized discomfort at the administration site.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate intervention. - Fluid overload: signs of pulmonary edema or heart failure. - Hemolysis: destruction of red blood cells observed in rare cases. - Thromboembolic events: clot formation in veins or arteries.

When using Nanoscint, clinicians should observe specific precautions to ensure patient safety and product integrity.

- Assess albumin levels: measure serum albumin before initiating therapy. - Monitor fluid balance: track input/output and signs of overload. - Evaluate cardiac function: consider underlying heart disease before volume expansion. - Use caution in renal impairment: adjust volume and monitor renal parameters. - Avoid concurrent use with other colloids unless clinically justified: may increase risk of volume overload. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nanoscint can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Diuretics: may exacerbate hypovolemia when combined with aggressive volume expansion. - ACE inhibitors or ARBs: increased risk of hypotension and renal impairment.

Moderate Interactions (Monitor Closely): - Vasopressors: may require dose adjustments due to altered intravascular volume. - Anticoagulants: monitor coagulation parameters as volume changes can affect drug distribution. - Other plasma expanders: combined use can lead to fluid overload.